VERU - ベル (Veru Inc.)


   Veru Stock Could Face Difficulties If the Culper Research Report Is True  2022/05/09 13:30:42 InvestorPlace
Veru (NASDAQ: VERU ) is set to discuss on May 10 with the Food and Drug Administration a pre-Emergency Use Authorization (EUA) meeting for its Phase 3 Covid-19 drug, sabizabulin (VERU-111). That could potentially be a turning point for Veru stock. However, the only problem is that there is a research report dated May 2 from a short-seller firm, Culper Research. The allegations the firm makes are of a nature that most potential investors in Veru stock are likely to read. To put bluntly the research report implies that Veru’s Phase 3 study is not likely to succeed in helping VERU-111 obtain a EUA. The report points out two major issues: first, the Phase 3 Covid-19 study contains “glaring issues, compounded by management misrepresentations.” For example, on April 11 Veru announced its Covid-19 drug brought down the mortality rate by 55% but the Culper report said that this was a manipulation of how high mortality rates were with Covid-19. Also, apparently, most of the patients in the study were outside of the U.S.
   The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru''s Pre-EUA Meeting, Conference Presentations And More  2022/05/09 12:33:09 Benzinga
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve''s 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ: IBB ), considered a proxy for the sector, shed close to 3 percent during the week. Penny stock and digital therapeutics company Better Therapeutics, Inc. (NASDAQ: BTTX ) more than doubled despite a lack of any meaningful catalysts. On the other hand, Connect Biopharma Holdings Limited (NASDAQ: CNTB ) lost more than half its market value after its investigational asset that is being evaluated for ulcerative colitis flunked a mid-stage trial. Earnings news flow also continued to move stocks in the space. Here are the key catalysts for biotech stocks in the unfolding week: Conferences World Federation of Hemophilia, or WFH, 2022 World Congress: May 8-11, in Montreal, Canada, as well as virtually BofA Securities 2022 Healthcare Conference: May 9–13, in Las Vegas, Nevada Psych Symposium: May 11, in London, U.K.
   Why Veru Stock Plummeted on Monday  2022/05/02 21:33:48 The Motley Fool
A short-seller makes some worrying accusations against the company.
   Veru Whale Trades Spotted  2022/05/02 20:07:01 Benzinga
A whale with a lot of money to spend has taken a noticeably bearish stance on Veru . Looking at options history for Veru (NASDAQ: VERU ) we detected 21 strange trades. If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened trades with bullish expectations and 57% with bearish. From the overall spotted trades, 4 are puts, for a total amount of $184,800 and 17, calls, for a total amount of $776,914. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $17.5 for Veru … Full story available on
   Veru gains after FDA grants pre-emergency use nod meeting date for COVID drug sabizabulin  2022/05/02 13:35:34 Seeking Alpha
Veru (VERU) stock has added 6.2% to $12.44 in Monday early trading, after the U.S
   Credit Suisse AG Raises Stock Position in Veru Inc. (NASDAQ:VERU)  2021/12/02 09:26:49 Dakota Financial News
Credit Suisse AG grew its stake in Veru Inc. (NASDAQ:VERU) by 159.5% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 28,857 shares of the companys stock after acquiring an additional 17,735 shares during the period. Credit Suisse AGs holdings in Veru were worth $232,000 as of []
   Veru Q4 2021 Earnings Preview  2021/12/01 16:30:42 Seeking Alpha
   Veru (VERU) Set to Announce Quarterly Earnings on Thursday  2021/11/30 06:40:41 Dakota Financial News
Veru (NASDAQ:VERU) will be issuing its quarterly earnings data before the market opens on Thursday, December 2nd. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Parties that wish to register for the companys conference call can do so using this link. Shares of VERU stock opened at $7.49 on []
   State Street Corp Has $8.42 Million Holdings in Veru Inc. (NASDAQ:VERU)  2021/11/26 09:38:41 Dakota Financial News
State Street Corp raised its position in shares of Veru Inc. (NASDAQ:VERU) by 19.6% in the second quarter, according to its most recent filing with the SEC. The firm owned 1,042,692 shares of the companys stock after purchasing an additional 170,617 shares during the quarter. State Street Corp owned approximately 1.31% of Veru worth $8,415,000 []
   Virtu Financial LLC Sells 57,919 Shares of Veru Inc. (NASDAQ:VERU)  2021/11/22 11:44:41 Dakota Financial News
Virtu Financial LLC trimmed its position in shares of Veru Inc. (NASDAQ:VERU) by 67.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,325 shares of the companys stock after selling 57,919 shares during the quarter. Virtu Financial LLCs []
   Veru to Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call on August 12th  2021/07/29 12:30:00 Intrado Digital Media
MIAMI, July 29, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that it will report financial results for its fiscal 2021 third quarter on Thursday, August 12, 2021, before the market opens. Verus management will host a conference call that same day at 8 a.m. ET to review the Companys performance and to answer questions. The call will also be accessible via webcast.
   Global Condoms Market to Reach $11 Billion by 2027  2021/07/15 09:43:00 Benzinga
New York, July 15, 2021 (GLOBE NEWSWIRE) -- announces the release of the report "Global Condoms Industry" - 7% over the period 2020-2027. Natural, one of the segments analyzed in the report, is projected to record 5.4% CAGR and reach US$7.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Synthetic segment is readjusted to a revised 6.2% CAGR for the next 7-year period. The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 7.2% CAGR The Condoms market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2027 trailing a CAGR of 7.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.7% and 5.2% respectively over the 2020-2027 period.
   Veru provides update on Phase 1b/2 study of sabizabulin in men with prostate cancer  2021/06/28 13:04:35 Seeking Alpha
   Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 European Association of Urology Annual Congress  2021/06/28 12:30:00 Intrado Digital Media
MIAMI, June 28, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers, today announced updated clinical results from the ongoing Phase 1b/2 clinical study of sabizabulin (VERU-111), an oral cytoskeleton disruptor being evaluated for the treatment of metastatic castration resistant prostate cancer in men who progressed on an androgen receptor targeting agent, were accepted for presentation at the European Association of Urology 36 th Annual Congress. The Congress is being held virtually from July 8-12, 2021.
   Enrollment underway in Veru''s mid-stage study of VERU-100 in hormone sensitive prostate cancer  2021/06/10 12:45:23 Seeking Alpha